<DOC>
	<DOCNO>NCT00692900</DOCNO>
	<brief_summary>The purpose study determine safe maximum tolerate dose regimen intraperitoneal oxaliplatin intravenous docetaxel intravenous oxaliplatin intraperitoneal docetaxel recurrent ovarian , primary peritoneal , fallopian tube cancer .</brief_summary>
	<brief_title>Safety Study Involving Oxaliplatin With Docetaxel Recurrent Ovarian , Primary Peritoneal , Fallopian Tube Cancer</brief_title>
	<detailed_description>This non-randomized , open-label Phase I trial patient previously treat , recurrent ovarian , primary peritoneal , fallopian tube cancer . Patients may either platinum -sensitive ( relapse &gt; 12 month primary therapy ) platinum-resistant ( relapse ≤ 12 month primary therapy ) disease . Up 20 patient enrol follow arm : - Arm 1 patient receive intravenous docetaxel standard dose 75 mg/m2 1 hour day # 1 follow intraperitoneal oxaliplatin day # 2 maximum tolerate dose achieve . - Arm 2 patient receive intravenous oxaliplatin standard dose 75 mg/m2 1 hour day # 1 follow intraperitoneal docetaxel day # 2 maximum tolerate dose achieve . Treatment repeat every 3 week disease progression , intolerable toxicity .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Recurrent histologically confirm platinumsensitive platinumresistant ovarian , primary peritoneal , fallopian tube cancer Subjects may &gt; 3 prior regimen must platinum taxane agent within past 6 month . Last chemotherapy must &gt; 4 week prior enrollment . Subjects may prior whole abdomen pelvic radiation . Patients may &gt; 6 cycle alkylating agent &gt; 450 mg/m2 doxorubicin . ECOG Performance Score ≤2 ( Appendix A ) Adequate bone marrow evidence : Absolute neutrophil count &gt; equal 1,500/uL Hemoglobin &gt; equal 8 g/dl Platelet count &gt; equal 100,000/uL Adequate renal function evidence serum creatinine &lt; 1.5 mg/dL Adequate hepatic function evidence : Serum total bilirubin &lt; 1.5 mg/dL Alk Phos , AST/ALT must &lt; 3x ULN &lt; 5x ULN hepatic mets . AST/ALT &lt; 3X ULN reference lab Patients must recover acute late effect prior surgery , radiotherapy antineoplastic therapy Patients legal representative must able read , understand provide inform consent participate trial . Patients childbearing potential partner must agree use effective form contraception study 90 day follow last dose study medication ( effective form contraception oral contraceptive double barrier method ) Patients active infection fever &gt; 101.30 F within 3 day first schedule day protocol treatment Patients active extraabdominal metastasis Patients active CNS metastasis . Patients stable CNS disease , undergone radiotherapy least 4 week prior plan first protocol treatment stable dose corticosteroid 3 week eligible trial History prior malignancy within past 5 year except curatively treat basal cell carcinoma skin cervical intraepithelial neoplasia Patients know hypersensitivity component docetaxel oxaliplatin Patients receive pelvic abdominal radiotherapy Patients receive concurrent investigational therapy receive investigational therapy within 30 day first schedule day protocol treatment ( investigational therapy define treatment currently regulatory authority approve indication ) Peripheral neuropathy ≤ Grade 2 Patients pregnant lactate Any medical condition , include mental illness substance abuse , deem Investigator likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result . History allogeneic transplant Known HIV Hepatitis B C ( active , previously treat )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>